August 2009 Volume 6 Number 8
Visit Nature Reviews Cardiology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=14&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to
Nature Reviews Cardiology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=45&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=64&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
*********************************************************************
Nature Reviews Cardiology Impact Factor: 5.972*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
NEW from Nature Reviews Cardiology: Molecular Imaging Series
http://links.ealert.nature.com/ctt?kn=28&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Reviews and Perspective articles from leading specialists in cardiovascular
imaging.
The Molecular Imaging Series covers every aspect of the visualization of
physiological and pathophysiological processes at the cellular and molecular
levels. With each issue of Nature Reviews Cardiology until spring 2010,
a molecular-imaging-focused paper will be published in print and added
to our online article series.
=====================================================================
----------------------
EDITORIAL
----------------------
Are predictive risk scores useful?
Valentin Fuster
p493 | doi:10.1038/nrcardio.2009.120
http://links.ealert.nature.com/ctt?kn=46&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Valvular disease: Treatment of ischemic mitral regurgitation
p495 | doi:10.1038/nrcardio.2009.107
http://links.ealert.nature.com/ctt?kn=59&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Diabetes: Early intensive insulin slows cardiovascular neuropathy
p496 | doi:10.1038/nrcardio.2009.109
http://links.ealert.nature.com/ctt?kn=60&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Prasugrel reduces all types of MI
p496 | doi:10.1038/nrcardio.2009.114
http://links.ealert.nature.com/ctt?kn=41&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Acute coronary syndromes: Risks and benefits of a new anticoagulant
p497 | doi:10.1038/nrcardio.2009.108
http://links.ealert.nature.com/ctt?kn=73&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
VT/VF: a marker oF POST-PCI outcome
p497 | doi:10.1038/nrcardio.2009.112
http://links.ealert.nature.com/ctt?kn=9&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Device therapy: Oral anticoagulation safe during cardiac device implantation
p497 | doi:10.1038/nrcardio.2009.113
http://links.ealert.nature.com/ctt?kn=16&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Atrial fibrillation: Symptoms of AF and HF improved by cardioversion
p498 | doi:10.1038/nrcardio.2009.110
http://links.ealert.nature.com/ctt?kn=36&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Prevention: BP lowering beneficial regardless of baseline level?
p498 | doi:10.1038/nrcardio.2009.111
http://links.ealert.nature.com/ctt?kn=58&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Thrombosis: Duration of anticoagulation after VTE: guided by ultrasound?
Henri Bounameaux and Marc Righini
p499 | doi:10.1038/nrcardio.2009.116
Patients with venous thromboembolism receive anticoagulants after a
thrombotic episode, usually for a fixed period. Discontinuing treatment
could lead to recurrence, but prolonged therapy can cause serious bleeding.
Ideally, treatment duration should be tailored to individual patients but
can this be achieved with ultrasonography, as proposed by the AESOPUS group?
http://links.ealert.nature.com/ctt?kn=76&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Interventional cardiology: A new drug-eluting stent that does not live up
to its promise
David R. Holmes Jr
p500 | doi:10.1038/nrcardio.2009.117
Drug-eluting stents are an established treatment option for coronary
artery disease, although they are not without their problems. The
MAHOROBA[reg] stent attempts to harness the theoretical advantages of both
tacrolimus and polymer degradation, but has proved not to be effective
in the treatment of de novo coronary lesions.
http://links.ealert.nature.com/ctt?kn=48&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Interventional cardiology: Effectiveness of stents in high-risk and
'real world' patients
Gennaro Sardella and Massimo Mancone
p502 | doi:10.1038/nrcardio.2009.115
There are concerns about long-term outcomes associated with drug-eluting
stent implantation in high-risk and 'real world' patients, and few data
from these settings have been published. Two new papers add to our knowledge
on drug-eluting stent use in acute myocardial infarction and for off-label
indications.
http://links.ealert.nature.com/ctt?kn=23&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Acute coronary syndromes: BNP measurement predicts AMI risk in the elderly
Eugene Braunwald
p503 | doi:10.1038/nrcardio.2009.118
With the aging of the population, the frequency of acute myocardial
infarction is rising most rapidly among the elderly, a subgroup at high
risk of a fatal outcome. Lorgis et al. observe that N-terminal pro-brain
natriuretic peptide, combined with a simple clinical risk score, provides
an accurate estimate of prognosis.
http://links.ealert.nature.com/ctt?kn=68&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Surgery for atrial fibrillation
Richard Lee, Jane Kruse and Patrick M. McCarthy
p505 | doi:10.1038/nrcardio.2009.106
Atrial fibrillation is a growing problem worldwide. Lee, Kruse and McCarthy
review surgical options for the treatment and cure of atrial fibrillation.
They discuss the classic maze procedure, new technologies that have allowed
minimally invasive modifications of this procedure, and the future directions
of surgical therapy for atrial fibrillation.
Abstract: http://links.ealert.nature.com/ctt?kn=29&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=57&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Targeting angiogenesis to restore the microcirculation after reperfused MI
Anja M. van der Laan, Jan J. Piek and Niels van Royen
Published online: 16 June 2009
p515 | doi:10.1038/nrcardio.2009.103
In a substantial group of patients with acute myocardial infarction,
reperfusion of myocardial tissue is hindered by dysfunction of the
microvasculature, despite successful restoration of the epicardial coronary
flow through percutaneous coronary intervention. This Review discusses the
role of angiogenesis in restoration of the microvasculature after reperfused
acute myocardial infarction.
Abstract: http://links.ealert.nature.com/ctt?kn=22&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=80&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Imaging outcomes in cardiovascular clinical trials
Louai Razzouk and Michael E. Farkouh
Published online: 30 June 2009
p524 | doi:10.1038/nrcardio.2009.104
As part of our series of articles focusing on molecular imaging, Drs Razzouk
and Farkouh explore the role of imaging in clinical trials and how
anatomical and functional parameters detected using imaging techniques are
being used as surrogate markers for clinical end points. The authors also
consider the impact of emerging imaging technologies on the future of
clinical trial design.
Abstract: http://links.ealert.nature.com/ctt?kn=44&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=79&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Gender differences in the cardiovascular effect of sex hormones
Cristiana Vitale, Michael E. Mendelsohn and Giuseppe M. C. Rosano
Published online: 30 June 2009
p532 | doi:10.1038/nrcardio.2009.105
Sex differences in vascular biology are determined not only by gender-related
differences in sex steroid levels, but also by gender-specific tissue and
cellular differences that mediate sex-specific responses to a variety of
stimuli. This Review discusses the influence of estrogen and testosterone
on the development of atherosclerosis, through direct vascular effects
and via effects on cardiovascular risk.
Abstract: http://links.ealert.nature.com/ctt?kn=4&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=33&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Biomarkers of abdominal aortic aneurysm progression. Part 2: inflammation
Femke A. M. V. I. Hellenthal, Willem A. Buurman, Will K. W. H. Wodzig and
Geert Willem H. Schurink
Published online: 23 June 2009
p543 | doi:10.1038/nrcardio.2009.102
In the second part of their Review on circulating biomarkers of abdominal
aortic aneurysm, Hellenthal et al. explore issues concerning the definition
of AAA progression, and examine the role of various markers of inflammatory
in predicting aortic expansion and rupture.
Abstract: http://links.ealert.nature.com/ctt?kn=3&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=72&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Hypertension Affects Everyone
Online Special
Bringing together more than 15 articles from the NPG hypertension portfolio,
Hypertension Affects Everyone features some of the latest research related
to the causes, affects and results of hypertension. This online special
provides you with FREE access to articles from American Journal of
Hypertension, Hypertension Research and Journal of Human Hypertension for
a limited time.
Take advantage of Hypertension Affects Everyone today!
http://links.ealert.nature.com/ctt?kn=32&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=34&m=33728434&r=MTc2NDI1MzEzNAS2&b=2&j=NTM5NjkyNDMS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
